Pharma Pulse 5/7/25: Teva Pharmaceutical’s Branded Drugs Boost First Quarter Profit, Theriva Biologics Announces Positive VIRAGE Phase IIb Results
Teva Pharmaceutical’s branded drugs boost first quarter profit
Teva Pharmaceutical’s first-quarter profit beat expectations thanks to surging sales of key branded drugs for migraines, Huntington’s disease, and schizophrenia, as the company continues shifting toward innovative therapies while maintaining its generics focus.
Theriva Biologics Announces Positive VIRAGE Phase 2b Results
Theriva Biologics reported positive Phase IIb results showing that VCN-01, combined with standard chemotherapy, significantly improved survival outcomes in metastatic pancreatic cancer, supporting its potential as a promising new treatment.
Alternative Strategies for Reducing Drug Costs: Q&A with Jesse Mendelsohn
In a Q&A with Pharmaceutical Executive, Jesse Mendelsohn, VP at Model N, cautions that proposed US drug tariffs may raise manufacturing costs without meaningfully reshoring production, and instead advocates for alternative strategies like domestic manufacturing incentives, structured Medicare negotiations, and enhanced pricing analytics to reduce drug costs and protect supply chains.
Four Strategic Considerations to Choose an EDC
In this Applied Clinical Trials article, industry experts outline four strategic considerations for selecting an electronic data capture system amid the evolving clinical data landscape (EDC), emphasizing that modern EDCs must support automation, integrate seamlessly with clinical data workbenches, and enable real-time access to reconciled, cross-source data in order to meet the demands of adaptive trials and multi-vendor environments.
AI at the Counter: How Artificial Intelligence is Shaping the Future of Pharmacy Practice
Artificial intelligence is transforming pharmacy practice by streamlining workflows, enhancing clinical decision-making, and enabling pharmacists to shift into more consultative roles, provided they actively engage in shaping these tools to preserve the human element of patient care.
Antares Vision Group, Siempharma Strike Up Pharma Labeling Equipment Collaboration
May 8th 2025The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.
